GeneDx, a leading genomics and clinical insights company, has announced that it will be releasing its financial results for the third quarter of 2023 on October 30, 2023. The results will be made available after the market closes, and a conference call will be hosted by Katherine Stueland, the President and Chief Executive Officer of GeneDx, and Kevin Feeley, the Chief Financial Officer of GeneDx, at 4:30 p.m. Eastern Time on the same day.
Investors who are interested in listening to the conference call are required to register online. Additionally, a live and archived webcast of the event will be accessible on the GeneDx investor relations website.
GeneDx is a company that focuses on delivering personalized and actionable health insights to improve the diagnosis, treatment, and drug discovery processes. Their expertise lies in utilizing genomic and large-scale clinical information to enable precision medicine as the standard of care. They are recognized for their exome and genome testing and interpretation, powered by one of the world’s largest rare disease data sets.
For more information, individuals can visit the GeneDx website and connect with the company on various social media platforms, including LinkedIn, Facebook, and Instagram.
Overall, GeneDx’s upcoming release of its Q3 2023 financial results, accompanied by a conference call led by the CEO and CFO, highlights the company’s commitment to transparency and communication with investors. This announcement further establishes GeneDx’s position as a leader in the field of genomics and clinical insights, as they continue to strive towards improving health outcomes through innovative solutions.
